KOL FMV Rates Pharmacist USA presents fair-market value compensation rates for US-based Pharmacist KOLs, by percentiles, with averages, for four (4) levels of Thought Leader influences (rare, international, national, and local).
These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs). All KOL FMV rates reports represent fair-market value established using our reliable methodology of collecting data from industry professionals involved in defining compensation levels for exchanges with KOLs worldwide.
Establishing fair-market value compensation rates will:
- reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.
- provide an independent reference for negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs).
- refine and support the development of fee schedules that are aligned with market conditions.
- competitively position the organization and support good business practices.
The data included in each report are an aggregate of collected data and not individual rates. In no event, companies and individuals who provided the data are identified to protect their identity.
Payments made to physicians and thought leaders have been under scrutiny for a few years and companies have been working to adjust their rates to level with industry standards.
Adjustments to market rates should be made periodically and are best done through 3rd party research, providing a fair and balanced assessment of rates. These payment benchmarks have proved to help legal, compliance, and Medical Affairs executives establish sound working relationships with Thought Leaders and Healthcare Professionals.
KOL FMV Rates Pharmacist USA
Nothing in this study constitutes financial or legal advice and we provide the contents of the study for information purposes only. This study may not be lent, resold, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published, without the prior written consent of the publisher.
INSIGHT
Research shows that less than 25% of pharmaceutical organizations begin working and involving Key Opinion Leaders during or before the clinical phase. Most - 63% - wait during phases 2 and 3 to start exchanging with Thought Leaders.
Table of Contents
- Use of the Publisher's Copyrighted Materials
- Research Methodology
- Definitions
- Therapeutic Area
- Thought Leader Levels
- Flat Rates
- Hourly Rates
Methodology
Analysts use primary and secondary research resources to develop our studies. The quantitative and qualitative data are collected through surveys and interviews conducted with professionals within the area of study. The data presented in our studies are an aggregate of survey and interview input. When possible, the data is presented by country. region or other factor to outline meaningful differences. We protect the identity and privacy of study participants and therefore blind their personal information and the organizations to which they belong - we only present the participation by company size and titles. This enables us to collect unbiased information, provided confidently by participants.
LOADING...
